Seaport Therapeutics, Inc. Form 8-K — Nov 2, 2026
Seaport Therapeutics (Nasdaq: SPTX) reported Q3 2026 financial results with a net loss of $26.4 million and cash, cash equivalents, and investments of $403.8 million, expected to fund operations into 2029. On the clinical side, the company announced positive topline data from a Phase 1 driving simulation trial showing GlyphAllo (375 mg evening dosing) did not impair next-morning driving performance versus placebo, and dosed the first patient in a Phase 2a trial of GlyphAgo in generalized anxiety disorder with sleep disturbance.
Key figures
- Revenue
- 0
- Total Assets
- 417624000
- Cash Position
- 403800000
- Cash runway
- into 2029
- Net loss q3 2025
- 22500000
- G and a expense q3 2026
- 6500000
- R and d expense q3 2026
- 23900000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.